Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Nightcap are a very new acquisitions company (no history) although the portfolio comprises mostly established venues, London based. I don't see the immediate read across at this stage.
Those of limited finances, whilst still appreciating a good time, also understand value and how to budget. They often 'load up' before entering a venue with fancy bar prices. The local 'offy' or somewhere like Spoons fits the bill.
Banbury, to briefly respond, Laughton has covered most aspects of what I had in mind. All policies are underwritten somewhere, even if not by Acromas (don't Acromas underwrite externally too?) and if cost of claims rise then it follows the underwriters will ask for more going forwards. Saga's 3 year fixed price policies don't tie the consumer (who is free not to renew) but tie the company if they do renew. If insurance pricing has fallen (say 7%) affecting policies being written recently but there are inflationary aspects going forwards, might that be a burden in years 2 and 3 or is that 'risk' covered by underwriters or otherwise hedged. 3 year may be a premium priced product but from what I've seen has discounted 'extras' (like recovery) built in.
Only if information and views are accurate. In fact the only reliable source of accurate information should be the company itself, assuming they provide timely guidance to the market in future and not allow a situation where insiders sell out in advance of profit warnings.
From the interims they are forecasting a full year loss. Perhaps a relatively small one ATM, but they need to show positive earnings and how.
That point was already reviewed earlier today if you would care to read further down the page, title header: "Youth".
When growth's not 'like for like' that suggests to me that is a change taking place. Perhaps also consider the lost year and fresh cohort of 18's.
As to 'this share going up' (sic) you couldn't be more mistaken Rod, maybe you need to think a bit deeper, or maybe you did already... I'm reminded of "chain letters", or maybe we should call it 'linked promotions'?
AFAIIA. there's been no news released in the past couple of days. So what else has gone on and where? Cui bono?
Whilst you ponder that, here's the suggestion you asked for: WOSG:LON
" Copied below is an extract from Wetherspoons’ trading update today; bodes well for RBG. "
Actually what that might be telling you is that there is migration to venues who sell at a cheaper price away from those with high(er) prices, hence bodes less well.
"MED3000 is a unique formulation of DermaSys® using volatile and non-volatile components tailored for the treatment of ED."
Fact is the control substance used in the trial was DermaSys and that lead to the study results that concluded there was little to choose between DermaSys + active ingredient and DermaSys on it's own. So the claim made was that manually applied DermaSys itself might be having some beneficial effect in respect of E.D. and those 'conclusions' were the basis for seeking EU and FDA approval. So, surely, it does not take much thinking to realise that MED3000 (Eroxon) cannot be materially different from DermaSys and "unique formulation" must be largely blandishment.
What it does best, in recent years, has been to make considerable losses. So let's hope not.
Malcy is just a sponsored promoter on most occasions AIUI.
"I think you're being unduly harsh."
I somehow doubt that might be your view if the sequence of guidance had been reversed.
Cautious is one thing, but this is rather stretching 'under promise, over perform' even in these circumstances, I feel. If they simply don't know, then that's fine, they can say so. But they chose to guide distributions as being 4 years away. Then, a few months down the line, in the space of a couple of weeks they find circa £3m, of which they explain £1.9m, the balance of £1.1m found down the back of the sofa? This during a period when, in general, outlets have been closed, transport and shipping costs have escalated, supplies have been disrupted and input prices have been rising. They suggest they have been on top of that, so how come they aren't, apparently, on top of the numbers. The point I'm making is that one would like them to be a bit more on top of the numbers as it spoils confidence going forwards to think that they might not be. This would apply to any business, it's not singling out Shoe in particular.
For a family run business one has to wonder how it is that they have been so far out with their guidance. In the space of a few months this has gone from no dividends before 2025, to £6.5m pre-tax profit, to £9-10m pre-tax profit.
The gain/ loss figures are illustrative only. There is no money invested. One could not open / trade a circa £100 position in Saga for 0.6% cost and as you have pointed out the s/p used is a 'fiddle' and them there is the issue of 'going short'. As illustrated a p/i could not physically replicate it. The nearest would be a derivative.